Eagle Health Investments LP Makes New $9.23 Million Investment in Revolution Medicines, Inc. $RVMD

Revolution Medicines’ stock (RVMD) is up nearly 100% YTD and about 285% over 12 months, as of the article’s writing. The clinical-stage biotech is developing RAS-addicted cancer drugs, led by daraxonrasib, which in a phase 3 metastatic pancreatic cancer trial showed overall survival of 13.2 months vs 6.7 with chemotherapy. The article cites analyst revenue forecasts above $1B and notes risks: no revenue, unprofitable, and a ~$33B valuation.

A Phase 3 trial reported by The Guardian found Revolution Medicines’ once-daily oral drug daraxonrasib improved outcomes in previously treated metastatic pancreatic cancer. In 500 patients, median survival was 13.2 months vs 6.7 months with chemotherapy, and the drug cut death risk by 60%. Severe side effects occurred in 43.6% vs 57.5%. The FDA plans a fast-track review and expanded access.

Revolution Medicines (NASDAQ:RVMD) said its experimental KRAS-mutant pancreatic cancer pill daraxonrasib more than doubled median overall survival versus chemotherapy in a pivotal trial of previously treated metastatic patients. The company reported a 60% reduction in risk of death and that the progression-free survival endpoint was met. It also said U.S. cancer centers are enrolling patients in an FDA-approved expanded access program.

Revolution Medicines reported Phase 3 RASolute 302 results for once-daily oral daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma. In a 500-patient global randomized trial, daraxonrasib cut the risk of death by 60% versus chemotherapy, raising median overall survival to 12.4 months from 6.7. Progression-free survival and response rates improved, with a manageable safety profile. Company says it will seek FDA priority review.

Bloomberg reports that Revolution Medicines’ daraxonrasib, a “molecular glue” drug, doubled median survival in aggressive pancreatic cancer from 6.7 to 13.2 months, with full phase 3 results expected at a Chicago conference. The success has spurred dealmaking and partnerships, including Monte Rosa’s potential $10B+ pacts with Novartis and Roche and J&J’s $3.05B Halda acquisition.

Revolution Medicines (RVMD) reported positive Phase 3 survival data for daraxonrasib in metastatic pancreatic cancer, boosting its investment narrative and potential for regulatory filing. While promising, the company faces significant cash burn and the challenge of translating these findings into a commercial asset. Investors should consider the forecasted $1 billion revenue and $148.6 million earnings by 2029 against the current high operating expenses and potential delays.